Evidence map›Paper›PMID 42488188›Full record

ArticleIranian journal of pharmaceutical research : IJPR

Novel Ethyl 2-Aminopyrano[3,2-c]isochromene-3-carboxylate Derivatives: Synthesis, Spectral Characterization, and Cytotoxicity.

Mehdi Abaszadeh, Fatemeh Haghani, Ehsan Faghihmirzaei, Salehe Sabouri

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mehdi AbaszadehPharmaceutics Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-4447-7199
Fatemeh HaghaniPharmaceutical Sciences and Cosmetic Products Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-9479-212X
Ehsan FaghihmirzaeiDepartment of Chemistry, University of Warwick, Coventry, United Kingdom.
Salehe SabouriHerbal and Traditional Medicines Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-9479-212X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer remains one of the most challenging threats to human health and has prompted intensive research in anticancer drug discovery and synthesis. Isocoumarins are natural lactones with several pharmacological activities, including cytotoxic and anticancer effects. Objectives: This study aimed to synthesize novel ethyl 2-aminopyrano[3,2-c]isochromene-3-carboxylate derivatives and evaluate their cytotoxicity against the MCF-7 breast cancer and A549 lung cancer cell lines, in comparison with a normal cell line (MCF-10A human breast cells). Methods: First, 4-hydroxyisocoumarin was prepared. A series of ethyl 2-aminopyrano[3,2-c]isochromene-3-carboxylate derivatives was then synthesized via a one-pot, three-component reaction of 4-hydroxyisocoumarin, ethyl cyanoacetate, and aromatic aldehydes in ethanol under reflux in the presence of triethylamine. The resulting compounds were characterized using standard spectroscopic techniques, including IR, Results: The compounds were successfully synthesized, and the cytotoxicity assay demonstrated dose-dependent cytotoxic effects in the tested cell lines. Most compounds exhibited moderate or low toxicity, whereas some were non-toxic in these cells. The most cytotoxic compounds were 4g, 4n, and 4m, with IC Conclusions: The compounds were synthesized in high yields and exhibited moderate-to-mild toxicity toward MCF-7, A549, and MCF-10A cells. Notably, halogen substitution at the ortho position of the phenyl ring increased toxicity, particularly in the MCF-7 cell line. However, the lack of selectivity observed for most compounds indicates that further structural refinement is required before this scaffold can be considered a viable anticancer lead.

Indexed as

2-c]isochromene-3-carboxylate Derivative4-hydroxyisocoumarinAnticancerAntineoplasticAntiproliferativeEthyl 2-aminopyrano[3Three-component Reaction

Identifiers

PMID42488188
PMCPMC13389371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.